Kinomica to Present Research Abstract on a Multi-drug Biomarker Signature to Predict Best First-line Treatments for Acute Myeloid Leukemia (AML) at the 2024 ASCO Annual Meeting

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Kinomica-ASCO-Meeting

More Like This

PR Newswire associated0

Advanced Method for Predicting Response to Midostaurin plus Chemotherapy in Acute Myeloid Leukaemia Greatly Outperforms Current Companion Diagnostic

PR Newswire associated0

Kinomica Announces Multiple Abstracts on its KScan® Precision Oncology Diagnostic Platform to be Presented at the 72nd Annual Meeting of the American Society for Mass Spectrometry

PR Newswire associated0

Kinomica, King's College London and King's College Hospital NHS Foundation Trust to Present Research Abstract at the 2024 ASCO Annual Meeting

Novotech Publishes Research Report on Acute Myeloid Leukaemia Clinical Trial Landscape for Clinical Stage Biotechs

PROTEINA Co., Ltd. Announces Breakthrough Research Published in Nature Biomedical Engineering

XNK Therapeutics presented two posters at the NK2023 conference in Oslo

Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress

PR Newswire associated0

MGI: Closing the Cancer Care Gap with the Power of Precision Oncology